Showing results (1-10 of 125) with videos related to
Sort By:
Pageof 13
Pharmaceutical Statistics|September 21, 2011
Determining the non-inferiority margin for patient reported outcomesChristoph Gerlinger, Thomas SchmelterMenopause (New York, N.Y.)|January 10, 2012
An empirically validated responder definition for the reduction of moderate to severe hot flushes in postmenopausal womenChristoph Gerlinger, Kerstin Gude, Florian Hiemeyer, et al.Menopause (New York, N.Y.)|August 22, 2013
A randomized, double-blind, placebo-controlled study of the lowest effective dose of drospirenone with 17β-estradiol for moderate to severe vasomotor symptoms in postmenopausal womenDavid F Archer, Thomas Schmelter, Matthias Schaefers, et al.Menopause (New York, N.Y.)|August 22, 2013
Population pharmacokinetic/pharmacodynamic evaluation of low-dose drospirenone with 17β-estradiol in postmenopausal women with moderate to severe vasomotor symptomsGabriele Sutter, Thomas Schmelter, Kerstin Gude, et al.Statistics in Medicine|July 6, 2007
Sperm count as a surrogate endpoint for male fertility controlNorbert Benda, Christoph GerlingerPsychiatrische Praxis|December 1, 2004
[Treatment of patients with personality disorders in specialized units for psychotherapy in Bavarian psychiatric hospitals]Thomas Schmelter, Rosemarie BauerBMJ Open|July 21, 2023
Substituting a randomised placebo control group with a historical placebo control in an endometriosis pain trial: a case study re-evaluating trial data using historical control data from another trialMarius Sieverding, Christoph Gerlinger, Christian SeitzEuropean Journal of Obstetrics, Gynecology, and Reproductive Biology|March 7, 2012
A historical cycle control comparison of two drospirenone-containing combined oral contraceptives: ethinylestradiol 30 μg/drospirenone 3 mg administered in a 21/7 regimen versus ethinylestradiol 20 μg/drospirenone 3 mg administered in a 24/4 regimenJoachim Marr, Christoph Gerlinger, Michael KunzActa Obstetricia Et Gynecologica Scandinavica|April 28, 2007
Denial of pregnancy--characteristics of women at riskJens Wessel, Annett Gauruder-Burmester, Christoph GerlingerDrugs - Real World Outcomes|June 14, 2020
Using Real-World Data to Predict Clinical and Economic Benefits of a Future Drug Based on its Target Product ProfileChristoph Gerlinger, Thomas Evers, Jeremy Rassen, et al.Pageof 13